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Aims Central sleep apnoea/Cheyne–Stokes respiration (CSA/CSR) is a risk factor for increased mortality and morbidity in
heart failure (HF). Adaptive servo-ventilation (ASV) is a non-invasive ventilation modality for the treatment of CSA/
CSR in patients with HF.
Methods SERVE-HF is a multinational, multicentre, randomized, parallel trial designed to assess the effects of addition of
ASV (PaceWaveTM, AutoSet CSTM; ResMed) to optimal medical management compared with medical management
alone (control group) in patients with symptomatic chronic HF, LVEF ≤ 45%, and predominant CSA. The trial is
based on an event-driven group sequential design, and the final analysis will be performed when 651 events have
been observed or the study is terminated at one of the two interim analyses. The aim is to randomize 1200 patients
to be followed for a minimum of 2 years. Patients are to stay in the trial up to study termination. The first patient was
randomized in February 2008 and the study is expected to end mid 2015. The primary combined endpoint is the
time to first event of all-cause death, unplanned hospitalization (or unplanned prolongation of a planned hospitalization)
for worsening (chronic) HF, cardiac transplantation, resuscitation of sudden cardiac arrest, or appropriate life-saving
shock for ventricular fibrillation or fast ventricular tachycardia in implantable cardioverter defibrillator patients.
Perspectives The SERVE-HF study is a randomized study that will provide important data on the effect of treatment with ASV on
morbidity and mortality, as well as the cost-effectiveness of this therapy, in patients with chronic HF and predomin-
antly CSA/CSR.
Trial
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Introduction
Up to 2–3% of the populations in many industrialized countries
have chronic heart failure (HF). Despite recent advances in
pharmacological treatment, HF continues to cause debilitating
symptoms, frequent hospital admissions, and high mortality. Al-
though guidelines recommend therapy with beta-blockers, ACE
inhibitors, and other pharmacological agents, as well as device-
based management such as CRT,1 many patients with HF have per-
sistent symptoms and most will eventually die from cardiovascular
causes, often from progressive HF.
Therefore, there is a need for new interventions that reduce
symptoms, increase quality of life, and reduce hospital admissions
and mortality in patients with chronic HF. It is likely that these
new interventions will be targeted at specific subgroups of HF
patients rather than the entire population. Treatment of sleep-
disordered breathing (SDB) may be one such intervention.
Sleep-disordered breathing is very common in patients with HF,
with reported prevalence rates of 50–75%.2,3 The presence of
SDB is associated with decreased survival in HF patients, while ef-
fective treatment of SDB could have beneficial effects.4 Two types
of abnormal breathing during sleep predominate in SDB: obstruct-
ive sleep apnoea (OSA) and central sleep apnoea (CSA), which
may manifest as Cheyne–Stokes respiration (CSR). There are
several mechanisms by which SDB may be detrimental to cardiac
function. These include tissue hypoxia and repetitive arousal
from sleep with increased sympathetic nervous system activity.5,6
Obstructive sleep apnoea is caused by obstruction of the upper
airway and is the most common type of sleep apnoea. The main
features are repetitive pauses in breathing during sleep (despite
breathing efforts) and reduced blood oxygen saturation. OSA is
present in 20–45% of chronic HF patients, a proportion that is
considerably higher than that in the general population.7,8
Treatment of OSA with continuous positive airway pressure
(CPAP) rapidly reduces tissue hypoxia and arousals, and, over a
period of months, reduces elevated sympathetic activity to
normal.9,10 CPAP has also been shown to reduce blood pres-
sure.11 –13 Two studies have demonstrated marked improvements
in cardiac function within 1 and 3 months of initiating CPAP treat-
ment of OSA,14,15 and the results of a cohort study suggest
improved survival in patients who are compliant with CPAP
therapy.16 However, no randomized long-term outcome studies
in OSA have yet been published.
Central sleep apnoea is characterized by a lack of drive to
breathe during sleep, resulting in repetitive periods of insufficient
ventilation and compromised oxygen supply. CSR consists of
periods of hyperventilation in association with waxing and
waning tidal volume alternating with periods of CSA. CSA/CSR is
the most common SDB pattern seen in the chronic HF population,
with a prevalence of 25–40%.7
Central sleep apnoea/Cheyne–Stokes respiration induces chem-
ical, neural, and haemodynamic changes similar to those seen in
OSA.5,6 It is an independent risk factor for death in these
patients,17 and one of the key underlying mechanisms for this
could be an increased risk for malignant ventricular arrhythmias.18
CSA/CSR can be treated with nasal oxygen, CPAP, or non-invasive
ventilation including adaptive servo-ventilation (ASV), in increasing
order of effectiveness.19 CPAP and oxygen therapy reduce respira-
tory events by 50%.
Adaptive servo-ventilation is a non-invasive ventilatory therapy
that provides positive expiratory airway pressure and inspiratory
pressure support, which is servo controlled based on monitoring
minute ventilation (MV). It automatically adjusts pressure support
to stabilize and reduce ventilation in patients with CSA/CSR. If
the patient stops breathing completely, the ventilator will maintain
ventilation at an automatically set respiratory rate.
One night of therapy with ASV improved the nocturnal breath-
ing pattern and sleep quality in patients with HF and CSA/CSR.19
Sleep and breathing were better during one night of ASV
therapy than during one night of treatment with oxygen or
CPAP, and patients preferred ASV over both CPAP and bilevel
ventilation. A small study showed beneficial effects in terms
of LVEF, disease-specific quality of life, and compliance after
6 months of ASV compared with CPAP.20 ASV has a greater
ability to reduce the respiratory event rate and normalize the
breathing pattern in many patients.19,20
The only randomized controlled trial investigating mortality in
patients with HF and CSA/CSR treated with CPAP was the
CANPAP study. The trial was stopped prematurely after enrol-
ment of 258 of the planned 408 patients, and data analysis did
not show a beneficial effect of CPAP treatment.21 However, a
post-hoc analysis suggested that morbidity and mortality might
be improved if SDB was well controlled.22
Although clinical experience with ASV is extensive, there is a
limited amount of published literature available. Several small
studies have shown improvements in symptoms and measures of
cardiac function, exercise tolerance, and quality of life with ASV
therapy.23– 25 Furthermore, a recent meta-analysis reported good
control of SDB and a significant improvement in LVEF in patients
with CSA/CSR treated with ASV.26
Studies to date have not been of adequate size or duration to
determine whether therapy with ASV is associated with significant
reductions in morbidity and mortality in patients with HF and CSA/
CSR. The SERVE-HF study was designed to address these issues.
Methods
Study design
SERVE-HF is a multinational, multicentre, randomized, parallel group
study. The trial is registered with Current Controlled Trials (www.
controlled-trials.com; ISRCTN19572887). Patients are being rando-
mized to optimal medical management (control group) or optimal
medical treatment plus ASV [PaceWaveTM, Auto Set CSTM; ResMed]
in a 1:1 ratio. There is no plan to provide sham positive airway pres-
sure treatment in the control arm. The study is event driven, with
an anticipated sample size of  1200. The first patient was randomized
in February 2008 and the study is expected to finish mid 2015. Patients
will be followed up on average for a period of  54 months. Minimum
follow-up time will be 24 months, and maximum 84 months. The
average follow-up time will depend on the speed of patient recruit-
ment. There will be a final assessment for each patient at the end of
the study.
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Objectives
The primary study endpoint (1a) is the time to first event: all-cause
death, unplanned hospitalization (or unplanned prolongation of a
planned hospitalization) for worsening chronic HF, cardiac transplant-
ation, resuscitation of sudden cardiac arrest or appropriate life-saving
shock for ventricular fibrillation and fast ventricular tachycardia in
implantable cardioverter defibrillator (ICD) patients, as assessed by
the Endpoint Review Committee (ERC). Two further co-primary end-
points are 1b (as for 1a, but with cardiovascular death instead of all-
cause death) and 1c (as for 1a, but with all-cause unplanned
hospitalization).
Secondary endpoints are as follows: time to death (non-
cardiovascular or cardiovascular); time to unplanned hospitalization;
proportion of follow-up days (%) during which patients are alive and
are not hospitalized; changes in general and disease-specific quality
of life and in HF symptoms; and change in 6 min walk distance. In add-
ition, a health economic analysis will be conducted to determine the
cost-effectiveness of ASV treatment.
For the substudy, the primary endpoint is the change in LVEF mea-
sured by echocardiography from baseline to 12 months. Secondary
substudy objectives are: ventricular remodelling assessed using echo-
cardiography; ventricular remodelling assessed using cardiac magnetic
resonance imaging (MRI); changes in sleep and respiratory parameters;
changes in disease-specific quality of life, cognitive function, and de-
pression [assessed using the Kansas City Cardiomyopathy Question-
naire,27 the Mini-Mental State Examination,28 the Patient Health
Questionnaire-9,29 and the Generalised Anxiety Disorder Question-
naire (GAD-7)];30 and changes in levels of NT-proBNP and other
biomarkers.
Patients
The intended population for this study is patients with HF and pre-
dominant CSA. Consecutive, eligible subjects meeting the detailed in-
clusion and exclusion criteria (Table 1) will be considered for the study.
Study plan, investigations, and treatment
The study schedule is shown in Figure 1. Clinic visits are scheduled for
all patients at study entry, after 2 weeks, after 3 and 12 months, and
every 12 months thereafter until the end of the study. Each of these
visits includes a blood sample (for measurement of haemoglobin,
serum creatinine, leucocytes and haematocrit), quality of life assess-
ment using the Minnesota Living with Heart Failure questionnaire
(MLHFQ) and the Euroqol questionnaire (EQ5D), determination of
sleepiness using the Epworth Sleepiness Scale (ESS), a 6 min walk
test (6MWT), and an ECG. Additional assessments include a general
history, medication history and event history for the time since the
last visit, a physical examination, and determination of NYHA class.
Furthermore, patients in the ASV group undergo polygraphy (PG) or
polysomnography (PSG) and a data download from the ASV device.
Patients are contacted by telephone at 6 and 18 months, and then
every 12 months.
Adaptive servo-ventilation is started in hospital. Use of a full face
mask is recommended for the initiation of therapy. Treatment is
started using standard settings, and pressure levels are adjusted
based on the results of respiratory monitoring. The PaceWaveTM
ASV algorithm sets the MV target to 90% of the patient’s own ventila-
tion. Patients are instructed to use the ASV device for at least 5 h each
night, 7 days a week. It is recommended that major mask leaks should
be avoided if possible. The target is to reduce the apnoea–hypopnoea
index (AHI) to ,10/h within 14 days of starting ASV. If this is shown
not to be the case at clinic visits (based on the data downloaded from
the ASV device), then proper mask fitting is again undertaken and
device settings adjusted for each patient individually.
SERVE-HF major substudy
The aim of the substudy is to assess ventricular remodelling, and
changes in left and right ventricular function, sleep, breathing, cognitive
function, anxiety, and depression. Evaluations to collect data for the
substudy (echocardiography, cardiac MRI, PSG, and questionnaires)
will be performed at baseline and at 3 and 12 months after
randomization.
Statistical considerations
Statistical methodology
Randomization will be stratified by site and by participation in the
major substudy, and is performed by the computerized electronic
case record form management system.
The primary analysis will be performed on adjudicated endpoints in
the intention-to-treat population (all randomized patients), following a
group sequential design with O’Brien–Fleming stopping boundaries.
The two interim analyses and the final analysis will be performed
when 50, 75, and 100% of the information has been collected, and
will consist of a two-sided log-rank test comparing the control and
intervention group, stratified by country (to account for possible dif-
ferences in event rates in the control group between countries).
The null hypothesis is that the time to first event in the intervention
group is identical to the time to first event in the control group. The
alternative hypothesis is that the time to first event in the intervention
group is different from the time to first event in the control group. The
test level and the rejection boundaries will depend on the interim ana-
lysis when the endpoint is analysed. At interim analysis 1, interim ana-
lysis 2, and the final analysis based on 325, 488, and 651 first events,
significance levels will be 0.0042, 0.0194, and 0.0430, respectively,
and the corresponding rejection boundaries of the standardized
log-rank statistic will be +2.863, +2.337, and +2.024, keeping an
overall two-sided significance level of 5%. To maintain study blinding,
the statistician of the Data and Safety Monitoring Board will link the
time-to-event data at each of the interim analyses to the randomization
code, calculate the log-rank statistic, and compare it with the pre-
defined limits.
Following the closed testing procedure of Lehmacher et al.,31 if the
null hypothesis for the first primary endpoint (all-cause mortality or
unplanned hospitalization for worsening HF) is not rejected, then
the testing ceases. Otherwise, testing proceeds to the second
primary endpoint (cardiovascular mortality or unplanned hospitaliza-
tion for worsening HF). If the null hypothesis for the second primary
endpoint is not rejected, then the testing ceases. Otherwise, testing
proceeds to the third primary endpoint (all-cause mortality or all-
cause unplanned hospitalization). Kaplan–Meier curves will be used
to visualize survival data.
Secondary analysis
Secondary endpoints will be analysed according to type of scale:
time-to-event endpoints will be analysed in the same ways as the
primary endpoint; dichotomous variables (improvement in NYHA
class) will be analysed by a likelihood x2 test; continuous endpoints
will be analysed by analysis of covariance (ANCOVA) including the
baseline value as a covariate if available; variables with right-skewed dis-
tributions within random groups will be log-transformed prior to ana-
lysis. All secondary endpoint comparisons will be performed at a ¼
0.05 without adjustment for multiplicity.
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Extended analyses will be conducted using regression models
(linear, logistic, or Cox proportional hazards) to explore further the
influence of patient characteristics and clinical conditions on
outcome. The list of covariates includes age, gender, country, site, co-
morbidities, severity of SDB (AHI 15–30 events/h, AHI ≥30 events/h),
NYHA class, ischaemic/non-ischaemic HF, and CSR ,20%/20–
50%/.50% of recording time to be determined at or immediately
after inclusion.
Sample size
The study was designed to demonstrate a 20% reduction in the
primary endpoint with an overall type 1 error rate of 5% two-sided in-
cluding two interim analyses and with a power of 80%. For this
purpose, a maximum of 651 events are to be observed if the study
will not be stopped at one of the interim analyses. To reach this
goal, that remained unchanged during the trial, a wide range of possible
recruitment and follow-up scenarios were considered at study start.
Eventually the study began with an assumption of a 35% control
group event rate per year and a recruitment goal of 70 patients/
month. These figures turned out to be not realistic. After a pre-
specified blind interim analysis of pooled data shortly before the
scheduled end of recruitment, a new sample size calculation was per-
formed, with the result that at least 1193 patients will be recruited
over a period of 60 months.
For the major substudy, a sample size of 300 patients was calculated
based on the assumption that ASV treatment will increase LVEF by 4%
over 12 months compared with baseline, with no change in LVEF in the
control group.
Ethics and monitoring
The Executive Steering Committee is responsible for the clinical and
scientific conduct of the study and publication of the results. An inde-
pendent Endpoint Review Committee reviews and adjudicates all pre-
specified events according to established definitions. Both committees
only have access to blinded data while the study is underway. There is
also an independent Data Safety Monitoring Board supervising the trial.
Members of the committees are listed in Appendix 1. The trial design
was approved by the local ethics committees. The trial is being con-
ducted in accordance with national laws, Good Clinical Practice, and
the Declaration of Helsinki 2002.
Discussion
Sleep-disordered breathing is common in patients with chronic HF
and is associated with adverse prognosis. Therefore, a treatment
that can control SDB has the potential to improve outcomes, as
well as quality of life, in patients with chronic HF. Such an overall
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Table 1 Trial inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
Age .21 years Significant COPD with FEV1 ,50% of predicted (European Respiratory
Society criteria) in the 4 weeks before randomization
Chronic HF (≥12 weeks since diagnosis) according to current European
Society of Cardiology guidelines1
Oxygen saturation ≤90% at rest during the day
LV systolic dysfunction (LVEF ≤45% determined using
echocardiography, radionuclide angiography, left ventriculography, or
cardiac magnetic resonance imaging) documented ,12 weeks before
randomization
Current use of PAP therapy
NYHA class III or IV, or NYHA class II with ≥1 hospitalization for
HF in the previous 24 months
Life expectancy ,1 year for diseases unrelated to chronic HF
No hospitalization for HF in the 4 weeks prior to enrolment Cardiac surgery, PCI, MI, or unstable angina within the previous 6 months
Optimized medical treatment according to applicable guidelines
with no new class of disease-modifying drug for ≥4 weeks prior
to randomization. Where there was no treatment with beta-blockers
or ACE inhibitors/ARBs, then the reasons must be documented
CRT implantation scheduled or performed within 6 months prior to
randomization
Predominant central SDB was defined as an AHI .15 events/h with
≥50% central events and a central AHI ≥10 events/h, derived from
PG or PSG and based on total recording time, documented within
4 weeks of randomization, with flow measurement performed using a
nasal cannula
TIA or stroke within the previous 3 months
Primary haemodynamically significant uncorrected valvular heart disease
(obstructive or regurgitant) or any valvular disease expected to require
surgery during the trial
Acute myocarditis/pericarditis within the previous 6 months
Untreated or therapy-refractory RLS
Contraindication to the use of AutoSet CS because of symptomatic
hypotension or significant intravascular volume depletion or
pneumothorax or pneumomediastinum
Pregnancy
AHI, apnoea–hypopnoea index; FEV1, forced expiratory volume in 1 s; HF, heart failure; MI, myocardial infarction; PAP, positive airway pressure; PG, polygraphy; PSG,
polysomnography; RLS, restless legs syndrome; SDB, sleep-disordered breathing; TIA, transient ischaemic attack.
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improvement in the HF symptom burden by targeting one co-
morbidity is an attractive proposition.
Continuous positive airway pressure treatment for OSA in cardio-
vascular disease is often recommended based on evidence of the
beneficial effects of CPAP on OSA in the general population.32,33 Al-
though there is some evidence for cardiovascular benefit of the
treatment of OSA,14,16,34 it is not yet known whether treatment of
CSA/CSR improves outcomes in patients with HF.
The CANPAP study is the only trial to date that investigated the
impact of positive airway pressure treatment (CPAP) on outcomes
(heart transplant-free survival) in patients with predominant CSA/
CSR.21 There was no overall survival benefit, but the results of a
post-hoc analysis suggested a potential benefit in patients for
whom CPAP was the most effective at attenuating CSA/CSR.22
Adaptive servo-ventilation therapy is currently the most effect-
ive treatment for CSA/CSR and is well tolerated. Use of ASV has
Figure 1 SERVE-HF Study plan. AE, adverse event; ASV, adaptive servo-ventilation; ESS, Epworth Sleepiness Scale; 6MWT, 6 min walk test;
PG, polygraphy; PSG, polysomnography; QoL, quality of life (* ¼ only performed in patients in the ASV group).
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been shown to improve multiple intermediate cardio-respiratory
endpoints in small groups of chronic HF patients.26 When compar-
ing ASV and CPAP, the improvements seen in ASV recipients were
considerably greater than those in patients treated with CPAP.20
Two observational cohort studies have recently reported that
positive airway pressure therapy for treatment of SDB in HF has
the potential to improve morbidity and mortality.4,35 Neither of
them reported the potentially different treatment effects of
CPAP and ASV. The German group only used ASV when CPAP
therapy failed to suppress CSA,4 whereas the French group
switched from using CPAP to ASV for the treatment of all patients
with CSA mid-way though their series of patients.35 However,
apart from the ongoing SERVE-HF trial, no prospective rando-
mized outcome study has been performed, and translation of
reported improvements to benefits in terms of mortality and mor-
bidity in patients with chronic HF has yet to be documented.
Conclusions
SERVE-HF is an important randomized controlled trial that will
assess, for the first time, whether treatment of predominant
CSA/CSR with ASV can reduce morbidity and mortality in patients
with chronic HF. The results of the SERVE-HF study should
provide further clarification of the benefits of effectively treating
CSA/CSR in patients with HF. In addition, the findings might
have important implications for individualized therapeutic strat-
egies targeted at reducing the morbidity and mortality, and
perhaps even the economic burden, of HF.
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